If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Bull Horn Holdings (BHSEU)
New Beginnings Acquisition (NBA.U)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Cerberus Telecom Acquisition (CTACU)
Upcoming IPO
OTR Acquisition (OTRAU)
Natural Order Acquisition (NOACU)
Priced IPO
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
EQT Corporation (EQT)
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
More companies

Athira Pharma, Inc. (ATHA)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. With their product candidates, they aim to provide rapid cognitive improvement and alter the course of neurological diseases with their novel mechanism of action. Their approach is designed to augment neuronal growth factor signaling through the HGF/MET, a naturally occurring regenerative system. Their pipeline is built from their proprietary drug discovery platform, or ATH platform, and consists of a series of small molecules that are designed to target either (1) the central nervous system, or CNS, by crossing the blood brain barrier, or BBB, or (2) the peripheral nervous system. Their lead candidate, ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule HGF/MET activator. In their Phase 1a and Phase 1b clinical trials, ATH-1017 for the treatment of Alzheimer’s disease, or AD, was well tolerated with no serious adverse events. These clinical trials recruited 88 subjects, including 11 subjects with mild-to-moderate AD. Nonclinical studies and Phase 1 clinical trials with ATH-1017 demonstrated improvements in brain network activity indicating potentially positive effects on brain function.
Leen Kawas Glenna Mileson
Employees Founded
15 2011


Address: 4000 Mason Road, Suite 300, Seattle, WA 98195, US

Telephone: (206) 221-8112

Web page:

IPO information

Expected Date 9/18/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $523.94
Revenues (MM) $0
Net Income (Loss) (MM) $-6.3


What do you think will happen with the ATHA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 10
Shares Revised (MM) 12
Expected offer amount (MM) $160
Realized offer amount(MM) $204
Goldman Sachs/ Jefferies/ Stifel
JMP Securities

Sector: Healthcare

Tweets about $ATHA

Tweets volume:

RT volume:


Google Trends Stats